$-7.82
(Market cap
$12 Mln
Recently Viewed
Clear AllMarket cap
$12 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
7.8
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-3.7 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-1.4
Debt to Equity
0
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
55,660,600
CFO
$-97.76 Mln
EBITDA
$8,290,586.27 Mln
Net Profit
$8,290,563.01 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
| -96.2 | -96.2 | -97.8 | -99.8 | -94.7 | -80.4 | -71.1 |
|
BSE Sensex*
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|---|
|
Kintara Therapeutics (KTRA)
| -97.5 | -73.0 | -60.2 | 85.6 | -79.8 | -68.4 | -65.8 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 | 11.7 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a... DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California. Read more
President, CEO, Interim CFO & Chairman of the Board
Mr. Robert E. Hoffman B.B.A., CPA
President, CEO, Interim CFO & Chairman of the Board
Mr. Robert E. Hoffman B.B.A., CPA
Headquarters
San Diego, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Kintara Therapeutics Inc (KTRA) is $0.23 (NASDAQ) as of 17-Oct-2024 19:49 EDT. Kintara Therapeutics Inc (KTRA) has given a return of -94.7% in the last 3 years.
Since, TTM earnings of Kintara Therapeutics Inc (KTRA) is negative, P/E ratio is not available.
The P/B ratio of Kintara Therapeutics Inc (KTRA) is 7.81 times as on 18-Oct-2024, a 71 premium to its peers’ median range of 4.57 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
--
|
--
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
The 52-week high and low of Kintara Therapeutics Inc (KTRA) are Rs -- and Rs -- as of 24-Apr-2026.
Kintara Therapeutics Inc (KTRA) has a market capitalisation of $ 12 Mln as on 18-Oct-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Kintara Therapeutics Inc (KTRA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.